FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations
- Details
- Category: Pfizer
Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Sanofi Pasteur to Develop & Commercialize Vaccine to Prevent Staphylococcus infections
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Stapyhylococcus aureus or MRSA.
GSK publishes speaking, consulting fees paid to US healthcare professionals
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline published a list of fees paid between April 1 and June 30 to U.S. healthcare professionals for speaking and consulting services. GSK will update this list quarterly going forward.
Array BioPharma and Amgen Partner in Type 2 Diabetes
- Details
- Category: Amgen
Array BioPharma Inc. (Nasdaq: ARRY) and Amgen Inc.(Nasdaq: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
Takeda and Pfizer to Co-Promote Takeda's Actos® for the Treatment of Type 2 Diabetes in China
- Details
- Category: Pfizer
Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Inc. ("Pfizer") announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China.
Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today a definitive agreement to acquire STARLIMS Technologies Ltd. (Nasdaq: LIMS), a leading provider of laboratory information management systems, for approximately $123 million in cash. The acquisition strengthens Abbott's competitive position in the global diagnostics market, providing advanced web-based applications to help laboratories efficiently store, retrieve and analyze a significantly increasing volume of clinical, managerial and administrative data.
GSK and Intercell form strategic alliance to develop and commercialise innovative vaccines
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline Biologicals SA (GSK) and Intercell announced an agreement to form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine for travellers' diarrhoea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK's portfolio.
More Pharma News ...
- Pfizer Extends Commitment to Help Unemployed Americans
- Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System
- Novartis Tasigna® trial shows superior results to Glivec®
- Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab
- Novo Nordisk starts phase 1 trial with oral insulin analogue
- Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
- New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists